课题基金 / 基金详情

BAYW6228 COMPARED TO PLACEBO & LOVASTATIN IN PTS W/ PRIMARY HYPERCHOLESTEROLEMIA

BAYW6228 COMPARED TO PLACEBO & LOVASTATIN IN PTS W/ PRIMARY HYPERCHOLESTEROLEMIA
BAYW6228 与安慰剂相比
批准号：
6116950
负责人：
D ROGER ILLINGWORTH
金额：
$3.13万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6116950
关键词：
antihypercholesterolemic agent blood lipoprotein biosynthesis clinical research clinical trials drug administration rate /duration drug screening /evaluation familial hyperlipoproteinemia type II human subject human therapy evaluation hypercholesterolemia inhibitor /antagonist lovastatin metabolism disorder chemotherapy placebos

项目摘要

项目成果

D ROGER ILLINGWORTH的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This study will evaluate the hypocholesterolemic effects and influence on cholesterol biosynthesis of the most potent inhibitor of cholesterol biosynthesis, BAYw6228, at doses of 50, 100, 200 and 300 ug/day in patients with primary hypercholesterolemia, As a control group, one oout of six patients will receive lovastatin (40 mg/day) and one out of six patients will receive placebo. Up to 30 patients will be involved in the study which will last for a total of 34 weeks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effects of simvastatin on postprandial hyperlipidemia
REGULAR AND SUSTAINED RELEASE SIMVISTATIN IN HYPERCHOLESTEROLEMIA
SIMVASTATIN ON STEROID HORMONE PRODUCTION IN MEN WITH HYPERCHOLESTEROLEMIA
THE EFFECTS OF HIGH DOSE SIMVASTATIN IN PRIMARY HYPERCHOLESTEROLEMIA